Novo Nordisk A/S (NVO) News

Novo Nordisk A/S (NVO)

Today's Latest Price: $64.83 USD

0.01 (0.02%)

Updated May 22 6:30pm

Add NVO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter NVO News Items

NVO News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Outlook on the Global Diabetes Disposable Insulin Delivery Pen Industry to 2026 - Major Players Analysed are Novo Nordisk, Eli Lilly & Sanofi Among Others -

DUBLIN--(BUSINESS WIRE)--The "Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026" report has been added to's offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe

Business Wire | May 22, 2020

'No team changes lives like our team.' How cycling's Team Novo Nordisk turned type 1 diabetes into its 'greatest strength'

Team Novo Nordisk, a professional cycling team made up of riders with type 1 diabetes, harbors a dream of competing at the Tour de France, the holy grail of road cycling.

CNN RSS | May 19, 2020

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Zacks Investment Research | May 8, 2020

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.

Zacks Investment Research | May 7, 2020

Insights on the Worldwide Insulin Delivery Device Industry to 2024 - Featuring Becton, Novo Nordisk & Medtronic Among Others -

DUBLIN--(BUSINESS WIRE)--The "Insulin Delivery Device Market Report: Trends, Forecast, and Competitive Analysis" report has been added to's offering. The future of the insulin delivery device market looks promising with opportunities in the patients/homecare and hospitals & clinics industries. The global insulin delivery device market is expected to grow with a CAGR of 9% from 2019 to 2024. The major growth drivers for this market are growing geriatric population base

Business Wire | April 29, 2020

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

Zacks Investment Research | April 29, 2020

The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutic...

Benzinga | April 28, 2020

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

Zacks Investment Research | April 14, 2020

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

Zacks Investment Research | April 6, 2020

Global Biologics Market: Insight, Competition and Forecast (2020-2025) Featuring Eli Lilly, Sanofi, Pfizer, Roche, AbbVie, Amgen, Merck & Co, Novo Nordisk, BMS, and Johnson & Johnson -

DUBLIN--(BUSINESS WIRE)--The "Global Biologics Market: Analysis By Product Type, Application Type, Product Pipeline, End User, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2020-2025)" report has been added to's offering. The Global Biologics Market was valued at USD 281.69 billion in the year 2019. Growing development of pipeline products and rapid economic growth with rising prevalence of chronic diseases and surging demand for low cost

Business Wire | March 6, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.704 seconds.